Do you want to read an article? Please log in or register.
Artificial intelligence for predicting BCG response in non-muscle-invasive bladder cancer: a systematic review
Genitourinary Cancer
Related content
COMMENTED
Genitourinary Cancer
Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Eur Urol
Scilipoti P, Zaurito P, Longoni M, Colecchia M, Montorsi F, Salonia A, Mercinelli C, Maiorano B, Necchi A, Briganti A, Moschini M
doi: 10.1016/j.eururo.2025.12.022
Breast Cancer
Current state of mammography-based artificial intelligence for future breast cancer risk prediction: a systematic review
J Natl Cancer Inst
Lowry KP, Jeong HE, Kim KH, Hughes KS, Lee CI, Yala A, Kerlikowske K, Vachon CM
doi: 10.1093/jnci/djag002
Genitourinary Cancer
Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial
Lancet Oncol
Tyson MD 2nd, Nam JK, Joshi SS, Uchio EM, Jung SI, Bivalacqua TJ, Steinberg GD, Shore ND, Burke JM, Kitamura H, Tran B, Li R
doi: 10.1016/S1470-2045(26)00194-4
Genitourinary Cancer
Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer
BJU Int
Scilipoti P, Zaurito P, Longoni M, Tremolada G, Occhi A, Dutto D, Katzendorn O, Krajewski W, Laukhtina E, Elena JLR, Aranda J, Contieri R, Hurle R, Subiela JD, Lucena PE, Fernández A, Marcq G, Szostek A, Pichler R, Álvarez-Maestro M, Bazán AA, Klatte T, du Biest AM, Ferrando V, Buisan O, López AV, Soria F, Pradere B, D Andrea D, Shariat SF, Colecchia M, Montorsi F, Briganti A, Gontero P, Xylinas E, Moschini M, European Association of Urology – Young Academic Urologists (EAU‐YAU), Urothelial Carcinoma Working Group and the EuroGemDoce Study Group Collaborators
doi: 10.1111/bju.70182
Genitourinary Cancer
Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle-Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab-Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials
Int J Cancer
Mangold MH, Baumann G, Wieland VLS, Carl N, Renner LV, Studier-Fischer A, Menold H, Zschäbitz S, Wessels F, Westhoff N, Michel MS, Kowalewski KF, Haney-Aubert CM
doi: 10.1002/ijc.70525
Genitourinary Cancer
Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta-analysis
BJU Int
Roessler N, Miszczyk M, Gontero P, Dematteis A, Miyajima K, Inoue S, Oberneder K, von Deimling M, Schuettfort VM, Vetterlein MW, Szabados B, Rajwa P, Karakiewicz PI, Teoh JY, Fisch M, Shariat SF
doi: 10.1111/bju.70214
Genitourinary Cancer
Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk non-muscle-invasive bladder cancer receiving intravesical bacillus Calmette-Guérin
J Urol
Bahlburg H, Maas M, Contreras-Sanz A, Othman D, St-Laurent MP, Nikkola J, Chai S, Phillips KG, Hamlington B, Lentz PS, Lumbres NP, Bicocca VT, Jalanko T, Levin TG, Lange D, Black PC
doi: 10.1097/JU.0000000000005130
Genitourinary Cancer
UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial
J Urol
Prasad SM, Shishkov D, Mihaylov NV, Genov P, Terzi V, Kates M, Huang WC, Louie MJ, Burger B, Meads A, Schoenberg M
doi: 10.1097/JU.0000000000005041
Genitourinary Cancer
Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer
BJU Int
Abou Chakra M, McElree IM, Mott SL, O'Donnell MA
doi: 10.1111/bju.70149